Welcome to our dedicated page for Privia Health Group SEC filings (Ticker: PRVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Privia Health Group, Inc. files SEC reports that document its physician enablement business, operating results, governance and public-company capital structure. Its 8-K reports commonly furnish quarterly and annual financial releases, including revenue, care margin, platform contribution, adjusted EBITDA, guidance, value-based risk arrangements and provider-network growth.
Proxy and other material-event filings cover board and committee governance, shareholder voting matters, material agreements, risk factors, regulatory disclosures and other updates tied to a Delaware corporation listed on Nasdaq under PRVA.
Privia Health Group, Inc. (PRVA) has a new significant shareholder group reporting a position in its common stock. Puma Growth Holdings, LLC and affiliated Rubicon Founders entities, together with Adam Boehler, report beneficial ownership of 6,472,513 shares of Privia common stock, representing 5.07% of the outstanding shares.
The group acquired Privia shares for investment purposes, using approximately $138.4 million of working capital. They state an intention to continue reviewing their investment and may communicate with Privia’s officers, directors, other stockholders, and third parties, which indicates an active-investor posture, though no specific plans or proposals are disclosed.
Privia Health Group, Inc. (symbol: PRVA) is the issuer of record for a Form 4 filing submitted to the SEC. Ernest Opella Finley reported acquisition or exercise transactions in this Form 4 filing.
Privia Health Group, Inc. (PRVA) reported that director Ernest Opella Finley received an award of 6,350 shares of common stock in the form of restricted stock units. The grant was made at $0.00 per share under the company’s 2021 Omnibus Incentive Plan and represents his entire reported direct holding after this award. According to the grant terms, these restricted stock units will become fully vested on the day immediately preceding the date of the company’s 2027 Annual Meeting of Stockholders. No Rule 10b5-1 trading plan is reported for this award.
Privia Health Group, Inc. (PRVA) had director Ernest Opella Finley file an initial statement of beneficial ownership as a new reporting person. The filing reports no transactions and no reportable equity or derivative positions in Privia Health Group at this time.
Privia Health Group, Inc. reported that its Board of Directors elected Opella Ernest, M.D. as a Class III director, effective September 1, 2026, and appointed her to the Board’s Compliance Committee on the same date. The Board determined she is independent under Nasdaq rules and disclosed no related-party arrangements or transactions requiring Regulation S-K Item 404(a) disclosure.
As a non-employee director, Dr. Ernest will receive an annual cash retainer under Privia’s Non-Employee Director Compensation Program and an annual equity grant of $200,000 in restricted stock units under the 2021 Omnibus Incentive Plan, with her initial grant pro-rated through the next annual stockholder meeting. Privia Health describes itself as a large physician enablement company operating in 25 states and the District of Columbia, supporting 1,300+ physician practices, serving 6.1+ million patients, and working with 5,600+ physicians and advanced practitioners.
Privia Health Group, Inc. generated higher results for the quarter ended June 30, 2026. Revenue was $632.6 million, up from $521.2 million a year earlier, and net income attributable to Privia Health Group, Inc. was $9.0 million versus $2.7 million. Adjusted EBITDA rose to $37.4 million.
Growth was driven by both fee-for-service and value-based care, with Practice Collections at $970.0 million, 5,644 Implemented Providers and 1.647 million Attributed Lives. Cash and cash equivalents were $412.2 million, total assets $1.49 billion, and there were no borrowings on an expanded $250 million revolving credit facility.
The company continues to expand geographically, including a 77% acquisition of a New Jersey medical group, and reports significant goodwill and intangible assets tied to payer contracts and physician networks. It also notes payer concentration among three large payers and an information request from federal and state authorities related to a former affiliated practice, which it is addressing in cooperation with the agencies.
Privia Health Group, Inc. reported strong second-quarter and year-to-date 2026 results, with total revenue of $632.6 million, up 21.4% from Q2 2025, and net income of $9.0 million, up 236.7%. Adjusted EBITDA, a non‑GAAP measure, increased 29.1% to $37.4 million.
Key operating metrics also expanded: Implemented Providers reached 5,644, Attributed Lives grew to 1,647,000, and Q2 Practice Collections rose to $970.0 million, supporting Care Margin of $132.1 million and Platform Contribution of $69.0 million. For the first six months of 2026, revenue was $1,236.5 million and Adjusted EBITDA was $74.1 million.
The company raised full‑year 2026 guidance for all key financial metrics, including Practice Collections of $3,650–$3,750 million, GAAP revenue of $2,350–$2,450 million, Care Margin of $515–$530 million, Platform Contribution of $260–$270 million and Adjusted EBITDA of $145–$155 million, and now expects Attributed Lives of 1,625,000–1,650,000. It expects approximately 70–80% of Adjusted EBITDA to convert to free cash flow in 2026, subject to timing of MSSP cash settlement, while maintaining cash and cash equivalents of $412.2 million at June 30, 2026.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 17,929,937 shares of Privia Health Group, Inc. common stock, representing 14.2% of the class. BlackRock reports sole voting power over 17,744,673 shares and sole dispositive power over 17,929,937 shares.
The filing notes that certain business units of BlackRock collectively hold these securities, and that iShares Core S&P Small-Cap ETF has an interest in more than five percent of Privia Health Group’s outstanding common stock.
Privia Health Group, Inc. executive vice president and chief financial officer David Mountcastle reported an open-market sale of 21,275 shares of common stock at a weighted average price of $27.67 per share, with individual sale prices ranging from $27.50 to $27.80. The sales were effected pursuant to a Rule 10b5-1 trading plan. Following the transaction, Mountcastle directly holds 164,853 shares, and an additional 8,695 shares are held indirectly by his spouse.
PRVA reporting person David Mountcastle sold common shares on multiple dates and filed related Form 144 notices. The excerpt lists executed sales: 7,179 shares on 05/01/2026 for $179,680.74; 1,206 shares on 05/04/2026 for $30,150.00; 3,385 shares on 05/11/2026 for $76,512.85; 17,196 shares on 06/26/2026 for $433,036.65; 24,734 shares on 07/02/2026 for $680,187.50; and 600 shares on 07/07/2026 for $16,539.00.
Privia Health Group, Inc. executive VP and chief financial officer David Mountcastle reported an open-market sale of 600 shares of common stock at a weighted average price of $27.57 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person.
After this transaction, he holds 186,128 shares directly and 8,695 shares indirectly through his spouse, according to the filing.